CEO Update | 1 August 2022

Innovative UK Genomics companies are vital to the future wealth of our nation

Last week we released our Genomics Nation 2022 report, in partnership with the Medicines Discovery Catapult and Wellcome Sanger Institute, which showcases the strengths and opportunities of this vibrant UK ecosystem of entrepreneurs, spin-outs and scale-ups.

The new data shows that UK genomics companies raised £1.9 billion in venture investment and £35.7 million in public grants since 2017, demonstrating the strength of this innovative sector.

Innovative UK Genomics companies are vital to the future wealth of our nation. With the right investment, skilled people and partnership working with the NHS family, UK small and medium-sized enterprises are ideally placed to be key global players in the growing subsectors within genomics such as functional genomics, epigenetics, transcriptomics and pharmacogenomics.  

The application and industrialization of this technology is transforming both healthcare and the pharmaceutical industry. Our growing sector needs great people who can use computational and data science skills to deliver our transforming health projects.

Key findings from the report include:

  • the genomics sector consists of 121 companies employing over 3,500 highly skilled people
  • has a market cap of over £3.5 billion based on deals since 2017
  • is young and growing, with half at early or seed stage
  • has a higher proportion of spin-outs (34%) compared to other sectors (2.7%)
  • relies on a range of skilled professionals, with 70% saying it was challenging to recruit for computational and data science skills.

BIA response to DHSC consultation on the future strategy for batch testing of medicines in Great Britain

The BIA has responded to the Department of Health and Social Care (DHSC) consultation on the future strategy for batch testing of medicines in Great Britain. The consolidated BIA response was developed with input from our Regulatory Affairs Advisory Committee. It is important that the consultation outcome supports the ambitions of the Life Sciences Vision and ensures that the UK retains and grows its reputation as a world-leading base for innovation and investment in R&D, while protecting patient safety and access to medicines, and maintaining globally harmonised standards.

Steve circle.png



Steve Bates OBE
CEO, BioIndustry Association

More news and updates

BIA Update | 15 August 2022

With the August lull and many people taking well-earned breaks, at BIA we are forging ahead with planning new events and new directions for 2023. As BIA membership continues to grow and thrive we face the challenge of continuing to connect and engage effectively with ever larger numbers of member companies and their employees, and we’re looking to address this with additional capabilities and exciting new initiatives.

EngBio Innovator Spotlight:

UK companies are working across a diverse range of applications of engineering biology. Featured in the 'Power of Biology: The UK is engineering biology for global good' report, the following case study highlights and gives additional insight into how this transformative technology can be used across healthcare, industry and agriculture. 

CEO Update | 8 August 2022

Summertime can be a quiet time but there has been a string of high-profile announcements within the UK sector to celebrate. Last week, RoslinCT announced that they have signed a business combination agreement with US advanced therapy CDMO Lykan Biosciences to form a global leading innovative advanced therapies CDMO. Read more on our engagement with the Labour Party and Biomedical Catalyst Round 2.

TechBio innovator spotlight: Faster, more accurate diagnosis of prostate cancer

Suspected prostate cancer cases need a biopsy, 80% of which result in complications. Improving diagnosis, using artificial intelligence with patient MRI scans, will reduce the risk of complications and speed up diagnosis.

More within